In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Retrophin Inc. (NASDAQ:RTRX) reported that Goldman Sachs Group Inc. has picked up 696,852 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Goldman Sachs Group Inc. to a total of 696,852 representing a 1.8% stake in the company.
For those not familiar with the company, Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.
A glance at Retrophin Inc. (NASDAQ:RTRX)’s key stats reveals a current market capitalization of 821.45 million based on 37.73 million shares outstanding and a price at last close of $21.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Meckler picked up 5,000 at a purchase price of $15.31. This brings their total holding to 52,000 as of the date of the filing.
On the sell side, the most recent transaction saw Aselage unload 3,200 shares at a sale price of $21.30. This brings their total holding to 240,556.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Retrophin Inc. (NASDAQ:RTRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.